Qifan Zhou is a Research Assistant Professor at the Grubbs Institute of SUSTech and holds a Category C Specially Appointed Position under Shenzhen's "Pengcheng Peacock Program". He is also a Senior Associate Engineer in Biotechnology. In 2019, he obtained his Ph.D. in Medicinal Chemistry from SYPU under the supervision of Prof. Guoliang Chen and was awarded the National Scholarship. His research primarily focuses on the discovery and development of small-molecule innovative drugs for the treatment of cancer, viral infections, and inflammation-related diseases. In 2020, he joined Prof. Xumu Zhang’s group at SUSTech, where he played a key role in the preclinical development of the novel oral anti-SARS-CoV-2 drug SHEN26, which has now completed Phase III clinical trial and is in the process of applying for market approval. Zhou has authored or co-authored over 20 SCI papers in journals such as Sci Transl Med, Signal Transduct Tar, Eur J Med Chem, and J Org Chem. He has also applied for more than 20 invention patents, with 9 Chinese patents granted as the primary inventor.

Educational background:

2016.09 – 2019.06   Ph.D., Medicinal Chemistry, SYPU
2012.09 – 2015.06   M.S., Medicinal Chemistry, SYPU
2007.09 – 2011.06   B.S., Environmental Science, SYPU

Work experience:

2023.11 – Present   Research Assistant Professor, Grubbs Institute, SUSTech
2023.01 – 2023.11   Research Director, Medi-X Pingshan, SUSTech
2021.01 – 2022.12   Postdoctoral Fellow, SUSTech

Research Area：

Small molecule drug development based on new mechanisms and new targets

Publications：

1. Qishu Chen1, Qifan Zhou1, Guanguan Li, Shuo Li, Yingjun Li* and Xumu Zhang*. Optimized kilogram-scale synthesis and impurity identification of SHEN26 (ATV014) for treating COVID-19. Organic Process Research & Development. 2023, doi.org/10.1021/acs.oprd.3c00248. (IF: 3.1)

2. Qifan Zhou1, Sidi Yang1, Liu Cao1, Yang Yang1, Tiefeng Xu, Qishu Chen, Hongzhou Lu, Yingjun Li*, Deyin Guo*, Xumu Zhang*. Preclinical characterization of SHEN26, an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside for the treatment of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2023, 8, 27. (IF: 40.8)

3. Qifan Zhou1, Yinzhu Luo1, Yujun Zhu1, Qishu Chen, Jingfei Qiu, Feng Cong*, Yingjun Li*, Xumu Zhang*. Nonsteroidal anti-inflammatory drugs (NSAIDs) and nucleotide analog GS-441524 conjugates with potent in vivo efficacy against coronaviruses. European Journal of Medicinal Chemistry, 2023, 249, 115113. (IF = 6.0)

4. Liu Cao1, Yingjun Li1, Sidi Yang1, Guanguan Li1, Qifan Zhou1, Jing Sun1, et al. The adenosine analogue prodrug ATV006 is orally bioavailable and has potent preclinical efficacy against SARS-CoV-2 and its variants. Science Translational Medicine, 2022, 14, eabm7621. (Co-author, IF=15.8)

5. Qifan Zhou, Lina Jia, Fangyu Du, Xiaoyu Dong, Wanyu Sun, Lihui Wang, Guoliang Chen*. Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents. New Journal of Chemistry, 2020, 44, 2247-2255. (IF = 3.925)

6. Fangyu Du1, Qifan Zhou1, Wenjiao Sun, Cheng Yang, Chunfu Wu, Lihui Wang* and Guoliang Chen*. 5-Hydroxyindole-based EZH2 inhibitors assembled via TCCA-catalyzed condensation and Nenitzescu reactions. Molecules, 2020, 25, 2059–2083. (IF = 4.927)

7. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Wenjiao Sun, Ying Wu, Guoliang Chen*. L-(-)-Quebrachitol as a ligand for selective copper (0)-catalyzed N‑arylation of nitrogen-containing heterocycles. Journal of Organic Chemistry, 2019, 84, 8160–8167. (IF = 4.198)

8. Qifan Zhou, Fangyu Du, Yuanguang Chen, Yang Fu, Guoliang Chen*. “On Water” promoted N-arylation reactions using Cu (0)/myo-inositol catalytic system. Tetrahedron Letters, 2019, 60, 1938–1941. (IF = 2.032)

9. Chunling Yuan1, Xiaoli Guo1, Qifan Zhou1, Fangyu Du, Xiaoyu Zhou, Peng Liu, Tianyan Chi, Xuefei Ji, Jinheng Gao, Chengwen Chen, Hongli Lang, Jia Xu, Danyang Liu, Yang Yang, Shimeng Qiu, Guoliang Chen* and Libo Zou*. OAB-14, a novel small molecule, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing <beta>-amyloid clearance in APP/PS1 mice. BBA-Molecular Basis of Disease, 2019, 1865, 161–180. (IF = 6.633)

10. Yajie Shi1, Qifan Zhou1, Fangyu Du, Yang Fu, Yang Du, Ting Fang and Guoliang Chen*. Iridium-catalyzed intramolecular C-N and C-O/S cross-coupling reactions: Preparation of benzoazole derivatives. Tetrahedron Letters, 2019, 60, 151082–151090. (IF = 2.032)

11. Fangyu Du1, Qifan Zhou1, Yang Fu, Yuanguang Chen, Ying Wu* and Guoliang Chen*. Copper(II)-catalyzed C–N coupling of aryl halides and N-nucleophiles promoted by quebrachitol or diethylene glycol. Synlett, 2019, 30, 2161–2168. (IF = 2.170)

12. Fangyu Du1, Qifan Zhou1, Yang Fu, Hanqi Zhao, Yuanguang Chen and Guoliang Chen*. tert-Butyl(3-cyano-4,6-dimethylpyridin-2-yl)carbonate as a green and chemoselective N-tert-butoxycarbonylation reagent. New Journal of Chemistry, 2019, 43, 6549–6554. (IF = 3.925)

13. Fangyu Du, Qifan Zhou, Xiaoxiao Fu, Yajie Shi, Yuanguang Chen, Wuhong Fang, Jingyu Yang* and Guoliang Chen*. Synthesis and biological evaluation of 2,2-dimethylbenzopyran derivatives as potent neuroprotection agents. RSC Advances, 2019, 9, 2498–2508. (IF = 4.036)

14. Fangyu Du, Qifan Zhou, Wenjiao Sun and Guoliang Chen*. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World Journal of Stem Cells, 2019, 11, 398–420. (IF = 5.247)

15. Fangyu Du, Qifan Zhou, Yajie Shi, Miao Yu, Wenjiao Sun and Guoliang Chen*. Synthesis of regorafenib through novel preparation of the intermediate 4-amino-3-fluorophenol via fries and Beckman rearrangements. Synthetic Communications, 2019, 49, 576–586. (IF = 1.937)

16. Caijiao Wu1, Qifan Zhou1, Dake Song, Hui Li, Changshun Bao, Xuelong Liu, Xuefei Bao and Guoliang Chen*. An improved process for the preparation of pimavanserin tartrate. Journal of Chemical Research, 2019, 43, 480-485. (IF = 1.097)

17. Qifan Zhou, Chen Peng, Fangyu Du, Linbo Zhou, Yajie Shi, Yang Du, Dongdong Liu, Wenjiao Sun, Meixia Zhang*, Guoliang Chen*. Design, synthesis and activity of BBI608 derivatives targeting on stem cells. European Journal of Medicinal Chemistry, 2018, 151, 39-50. (IF = 6.0)

18. Qifan Zhou, Fangyu Du, Xinjie Liang, Wenqiang Liu, Ting Fang and Guoliang Chen*. Zinc (II)-mediated selective O-benzylation of 2-oxo-1,2-dihydropyridines systems. Molecules, 2018, 23, 1784-1798. (IF = 4.927)

19. Qifan Zhou, Fangyu Du, Yajie Shi, Wenqiang Liu, Dongdong Liu and Guoliang Chen*. An efficient protocol for the production of pymetrozine via a new synthetic strategy. Journal of Chemical Research, 2018, 42, 395-446. (IF = 1.097)

20. Qifan Zhou, Fangyu Du, Yajie Shi, Ting Fang, Guoliang Chen*. The synthesis and analysis of 1-methyl-4-phenyl-1H-imidazol-2-amine and by-products. Journal of Chemical Research, 2018, 42, 608–610. (IF = 1.097)

21. Fangyu Du, Qifan Zhou, Dongdong Liu, Ting Fang, Yajie Shi, Yang Du, Guoliang Chen*. Dimerization of aromatic compounds using palladium-carbon catalyzed Suzuki–Miyaura cross-coupling by one-pot synthesis. Synlett, 2018, 29, 779-784. (IF = 2.170)